Fda finalized the bioavailability and bioequivalence regulations on january 7, 1977 42 fr 1624, and amended these regulations on april 28, 1992 57 fr 17950. Bioavailability and bioequivalence studies submitted in. Submission of summary bioequivalence data for abbreviated. Although this collection contains information of a legal nature, it has been developed for informational purposes only and does not constitute legal advice or opinions as to the current operative laws, regulations, or guidelines of any jurisdiction.
Determination of bioequivalence for drugs with narrow. Study on requirements of bioequivalence for registration. If prodrugs have low plasma concentrations, it is acceptable to demonstrate bioequivalence for the main active metabolite without measurement of parent compound. Pdf study of regulatory requirements for the conduct of. Introduction this guidance document provides information about how to establish and conduct bioavailability studies for conventional formulations of oral drugs that are used for systemic effects. Sampling points also vary with respect to the regulatory guidelines of these countries. Talk with your doctor and family members or friends about deciding to join a study. The information on this page is current as of april 1 2019. The use of semi or partial replicated designs is also allowed, since blood volume might be a problem for 4period studies.
This is interesting to potential sponsors of bioequivalence be studies and to those interested in regulatory sciences. The studies were conducted in healthy human volunteers in both fasting and fed conditions as per the us regulatory requirements for conduct of bioequivalence studies. Importance of bioequivalence studies for enhancing. Significance of be studies bioequivalence studies are intended to look at the in vivo execution of a test pharmaceutical item multisource contrasted with a reference pharmaceutical item. Regulatory requirements in bioequivalence high impact list of articles ppts. In determining bioequivalence, for example, between two products such as a commercially available brand product and a potential tobemarketed generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a crossover study to volunteer subjects, generally healthy individuals but occasionally in patients. Bioequivalence bioequivalence is defined to the class using the terms provided in section 505j7b of the federal food, drug, and cosmetic act. The present study highlights the relevant regulatory guidelines for the conduct of bioequivalence studies in us, europe, canada, india, south africa and south east asian nations.
Bioequivalence study bioequivalence study should be performed according to sec. Pulla reddy college of pharmacy, osmania university, hyderabad, india 2 department of pharmaceutical analysis, vathsalya college of pharmacy, jawaharlal nehru technology university, hyderabad, india. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. The conduct of bioequivalence studies in the following sections, requirements for the design and conduct of bioequivalence studies are. The new guidance has a number of new and even novel features. This comprehensive reference provides an indepth discussion on stateoftheart regulatory science in bioequivalence. Study of regulatory requirements for the conduct of. Bioequivalence studies are crossover studies in which each subject acts as their own control. Subsequently, another draft guidance was issued on the bioequivalence of tacrolimus. Handbook of bioequivalence testing crc press book as the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies.
Bioequivalence range31 acceptable range of bioequivalence is generally 0. Fda regulations in part 320 21 cfr part 320 establish definitions and requirements for bioavailability and bioequivalence studies. An overview on bioequivalence regulatory requirements of orally. For both, these studies are also important in the postapproval period in the presence of certain manufacturing changes. Applying for a bcsbased biowaiver is restricted to highly soluble drug substances with known. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. Review on bioavailability and bioequivalence studies. Study of regulatory requirements for the conduct of bioequivalence studies in us, europe, canada, india, asean and sadc countries. Guideline for bioequivalence studies for different oral. The use of a metabolite as a surrogate for an active parent compound is not encouraged. Project director center for bioequivalence studies and bioassay research international center for chemical and biological sciences university of karachi pakistan. Guide for the bioequivalencemodule 5 3 if applicable, both sex male and females should be included in the study design. Before going into bioequivalence studies it is essential for the pharmaceutical industry to study the guidelines of bioequivalence for the respective country where the industry wants to market.
Informal communication by the center for drug evaluation and research cder, march 2003 rani s, pargal a. A typical outline for a bioequivalence study includes organization of the test and. Table 9 regulatory criteria on number of studies required for conducting. Choosing to participate in a study is an important personal decision. The present study was designed to assess bioequivalence between a fingolimod test capsule formulation teva argentina, formerly ivax argentina s. Bioavailability andor bioequivalence studies play a key role in the drug development period for both new drug products and their generic equivalents.
Design and conduct of bioequivalence studies the basis of a bioequivalence study is the comparison of the drug product to be tested with an appropriate reference product branded innovator drug. The main focus of this lecture is to instruct students in process and requirements needed to attain the ab rating. The fda considers two products bioequivalent if the 90% ci of the relative mean cmax, auc 0t and auc 0. Potential new method to improve bioequivalence be of modified release mr drug products by in vivo dissolution studies in human gi tract. Study of regulatory requirements for the conduct of bioequivalence. The 7575 states that at least 75% of the subjects must show a bioavailability value for the new formulation that is at least 75% of the corresponding bioavailability measurement for the. Like many regulatory studies, the assessment of bioavailability and bioequivalence can generally be achieved by. As mauricio said, there isnt a specific guideline determining the anova structure for replicated designs, but ive always used fdas suggestion appendix e of 2001 guidance without problems. A comparative study of the differences in study design and specifications have also been addressed.
Its commonly observed that there are several formulations of the same drug, in the same dose, in similar dosage form and meant to be given by the same route. Be studies and indicated steps to make certain that the information became part of regulatory processes and drug development. The assessment of be of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar. These studies are often done for generic drugs or when a formulation of a drug is changed during development. Comparative bioavailability studies should be conducted in accordance with generally accepted clinical practices that are designed to ensure the protection of the rights, safety and wellbeing of subjects and the good clinical practices referred to in division 5 of the regulations and described in the international conference on harmonisation ich guidance topic e6 on good clinical practice. Bioequivalence and bioavailability forum anvisa and. Bioequivalence study full text view clinicaltrials. Although there are a few exceptions, generally a bioequivalent comparison of test to reference.
It should be noted that bioequivalence cannot be used for extrapolation of withdrawal periods between injectable products for intramuscular andor subcutaneous injection in food producing animals. Bioequivalence and bioavailability, pre conference workshop budapest, 11 may 2009 3 69 57 statistical design and analysis i informa life scienceslife sciences defining study objectives according to the eu nfg 3. Bioavailability and bioequivalence studies marc sturgill, pharm. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, biopharmaceutics classification systems. Bioequivalence concept regulations exist worldwide to assure quality, safety, and efficacy of medicines the bioequivalence be concept addresses the safety and efficacy issue for generic drug registration be provides the bridge from the generic product to the innovators clinical and nonclinical studies and. Bioequivalence studies are special type of studies where two drugs or two sets of formulation of the same drug are compared to show that they have nearly equal bioavailability and pkpd parameters. Regulatory requirements in bioequivalence list of high impact.
New requirements should be based on a demonstrated. The requirements of the guideline on investigation of chiral active substances as far as relevant for bioavailability and bioequivalence studies should be taken into account for products containing chiral active substances. In vivo bioequivalence studies may be exempted if an assumption of equivalence in in vivo performance can be justified by satisfactory in vitro data. Pdf bioavailability ba and bioequivalence be studies play a major role in the. Tasneem ahmad, cbsbr, university of karachi 1 selection of be study design estimation of sample size number of volunteers 800 calculation of bioavailability ba. What is bioavailability and bioequivalence generics 2009. Importance of bioequivalence studies for enhancing pharmacokinetic parameters rita b 1, akhilesh t 2. Bioequivalence studies in drug development focuses on the planning, conducting, analysing and reporting of bioequivalence studies, covering all aspects required by regulatory authorities. Demonstration of bioequivalence for parent compound is recommended for inactive prodrugs. For instance, it would be clinically useful to evaluate fastrelease drugs versus those with a delayed response also trade names versus generic ones. This model, in vivo healthy volunteers is regarded as adequate to detect formulation differences. This document is intended to provide the principal requirements for reproductive health medicines.
The present study was aimed to study the requirements of bioequivalence for the registration of pharmaceutical products in the usa, europe and canada. Bioequivalence studies compare both the rate and extent of absorption of various multisource drug formulations with the innovator reference product, on the basis that if two formulations exhibit similar drug concentrationtime profile in the bloodplasma, they should exhibit similar therapeutic effects three situations have thus. Guidance on bioequivalence studies for reproductive health. A bioequivalence study is basically a comparative bioavailability study. Statistical analysis of bioequivalence studies school of statistics and actuarial science by mavuto nyathi 576994 supervisor renette krommenhoek a research report submitted to the faculty of science in partial fulfilment of the requirements for the degree of master of science 26 october 2016. Guideline for bioequivalence studies of generic products december,2006. Food effect bioavailability studies are usually conducted for new drugs and drug products during the investigational new drug ind period to assess the effects of food on the rate and extent of absorption of a drug when the drug product is administered shortly after a meal fed conditions, as compared to administration under. Furthermore, a bioequivalence trial information form should be completed in ms word format for. Overview of test designs invivo bioequivalence studies. Bioequivalence who prequalification of medicines programme. Foodeffect bioavailability and fed bioequivalence studies.
Study on requirements of bioequivalence for registration of. Pdf the basic regulatory considerations and prospects for. This article provides the information about important aspect involved in bioequivalence and regulatory requirment for bioequivalence study. In the case of entericcoated products, the change in the diameter of the units forming the dosage forms and. Fdas final rule on requirements for submission of bioequivalence data the be data rule requires an anda applicant to submit data from all be studies the applicant conducts on a drug.
Fingolimod is an oral agent approved for the treatment of relapsing forms of multiple sclerosis ms, which has demonstrated efficacy in phase iii trials in patients with relapsingremitting ms rrms. In bioequivalence studies, the plasma concentration time curve is generally to assess the rate and extent of absorption. For the most uptodate version of cfr title 21, go to the electronic code of federal regulations ecfr. In bioequivalence studies an applicant compares the systemic exposure profile of a test drug to that of a reference drug product. Regulatory requirements in bioequivalence list of high. Further more, phannacokinetics parameters of 21 oh deflazacort was investigated for test formulation against reference formulation.
Choosing the reference batch unless otherwise justified, the assayed content of the batch used as test product should not differ more than 5% from that of the batch used as reference product determined with the test. A bioequivalence study report that is submitted as a product dossier must comply with who guidance for bioequivalence studies and who guidelines for good clinical practice. The results obtained allow extrapolation to populations in which the reference product is approved e. Sample size and power analysis in bioequivalence studies.
388 497 931 720 926 1241 710 455 1458 759 984 497 371 1422 1175 1083 292 456 1162 1026 466 245 1198 529 36 676 796 1050 234 417 1350 1089 545 441 193 724 237 722 911